Search Results

You are looking at 1 - 10 of 775 items for :

  • "risk factor" x
  • Refine by Access: Content accessible to Me x
Clear All
Full access

Paul S. White, Michael Dennis, Eric A. Jones, Janice M. Weinberg, and Shayna Sarosiek

-institution retrospective study, we sought to identify the prevalence of hypocalcemia and determine the risk factors for development of hypocalcemia in a diverse, multiracial population of patients with cancer receiving treatment with BMAs. Patients and Methods We performed

Full access

Adam J. Olszewski, Kalyan C. Mantripragada, and Jorge J. Castillo

risk factors for death and hospitalization during the first month of rituximab-based immunochemotherapy using population-based data from Medicare beneficiaries. Patients and Methods Data Source and Cohort Selection This study used

Full access

Jeremy Lund, Angela Pearson, and Georgia Keriazes

call for a multidisciplinary, coordinated effort to identify potential risk factors for readmission. 2 With the recent changes to repayment structures by CMS for selected diagnoses and the prospect of that list growing, it is imperative for

Full access

Michael B. Streiff, Bjorn Holmstrom, Dana Angelini, Aneel Ashrani, Amro Elshoury, John Fanikos, Kleber Yotsumoto Fertrin, Annemarie E. Fogerty, Shuwei Gao, Samuel Z. Goldhaber, Krishna Gundabolu, Ibrahim Ibrahim, Eric Kraut, Andrew D. Leavitt, Alfred Lee, Jason T. Lee, Ming Lim, Janelle Mann, Karlyn Martin, Brandon McMahon, John Moriarty, Colleen Morton, Thomas L. Ortel, Rita Paschal, Jordan Schaefer, Sanford Shattil, Tanya Siddiqi, Deepak Sudheendra, Eliot Williams, Liz Hollinger, and Mai Q. Nguyen

update of the NCCN Guidelines are available at NCCN.org. VTE Risk Assessment in Patients With Cancer VTE risk factors in patients with cancer can be grouped into 3 general categories: patient-related factors, cancer-related factors, and treatment

Full access

Mohammad Abu Zaid, Wambui G. Gathirua-Mwangi, Chunkit Fung, Patrick O. Monahan, Omar El-Charif, Annalynn M. Williams, Darren R. Feldman, Robert J. Hamilton, David J. Vaughn, Clair J. Beard, Ryan Cook, Sandra K. Althouse, Shirin Ardeshir-Rouhani-Fard, Paul C. Dinh Jr, Howard D. Sesso, Lawrence H. Einhorn, Sophie D. Fossa, Lois B. Travis, and for the Platinum Study Group

disease (CVD) compared with controls. 8 – 13 In the general population, metabolic syndrome (MetS) is a major risk factor for CVD. 14 MetS is a constellation of interrelated CVD risk factors, including insulin resistance, hypertension, elevated

Full access

Grace L. Smith, Maria A. Lopez-Olivo, Pragati G. Advani, Matthew S. Ning, Yimin Geng, Sharon H. Giordano, and Robert J. Volk

and intervention in vulnerable patients, 18 a comprehensive synthesis of the risk factors for and outcomes of financial burdens is needed. We therefore conducted a systematic review of these risk factors and outcomes across studies of US patients with

Full access

Leila Family, Yanli Li, Lie Hong Chen, John H. Page, Zandra K. Klippel, and Chun Chao

of a given patient's FN risk depends on knowledge of key FN risk factors. The performance of currently available FN prediction models in the literature indicated room for improvement in clinical FN risk prediction. 18 , 19 Thus, the objective of this

Full access

Derek Weycker, Xiaoyan Li, Rich Barron, Hongsheng Wu, P.K. Morrow, Hairong Xu, Maureen Reiner, Jacob Garcia, Shivani K. Mhatre, and Gary H. Lyman

-stimulating factor (CSF) when risk, based on the chemotherapy regimen and patient risk factors, is “high” (>20%) (to view the most recent version of these guidelines, visit NCCN.org ). For patients whose risk is high based on the chemotherapy regimen alone, the

Full access

Fangwen Zou, Hamzah Abu-Sbeih, Weijie Ma, Yuanzun Peng, Wei Qiao, Jianbo Wang, Amishi Y. Shah, Isabella C. Glitza Oliva, Sarina A. Piha-Paul, John A. Thompson, Hao Chi Zhang, Anusha S. Thomas, and Yinghong Wang

the risk factors for chronic IMDC or its effects on the overall cancer outcome. We attempted to bridge this knowledge gap in a retrospective study of patients with advanced malignancies at The University of Texas MD Anderson Cancer Center (MDACC

Full access

Sumer K. Wallace, Jeff F. Lin, William A. Cliby, Gary S. Leiserowitz, Ana I. Tergas, and Robert E. Bristow

) view/print certificate. Release date: May 12, 2016; Expiration date: May 12, 2017 Learning Objectives Upon completion of this activity, participants will be able to: Identify risk factors associated with refusal of recommended chemotherapy